(andusomeran mRNA vaccine)

Resources for Canadian Healthcare Professionals and Patients

SPIKEVAX® XBB.1.5 (andusomeran mRNA vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 6 months of age and older.

The National Advisory Committee on Immunization (NACI) strongly recommends a dose of the new formulation of COVID-19 vaccine for individuals in the authorized age group if it has been at least 6 months from the previous COVID-19 vaccine dose or known SARS-CoV-2 infection (whichever is later). Immunization is particularly important for those at increased risk of COVID-19 infection or severe disease, for example: 

  • Adults 65 years of age or older 

  • Residents of long-term care homes and other congregate living settings 

  • Individuals with underlying medical conditions that place them at higher risk of severe COVID-19 

  • Individuals who are pregnant 

  • Individuals in or from First Nations, Métis and Inuit communities* 

  • Members of racialized and other equity-deserving communities 

  • People who provide essential community services 

Click here for the full NACI recommendation as of July 11, 2023.

The current SPIKEVAX XBB.1.5 vial and carton labels are not Canadian-specific, as global, English-only labels are being used for the Canadian market.  

For more information, please see the Notice of English-Only Labelling below. 

Please find helpful resources for SPIKEVAX XBB.1.5 below. Check back as we update with additional educational content as it becomes available. 

0.10 mg/mL Drug Identification Number (DIN): 02541270

* Autonomous decisions should be made by Indigenous Peoples with the support of healthcare and public health partners in accordance with the United Nations Declaration on the Rights of Indigenous Peoples.


Dosage, Administration, Storage, and Handling (DASH)
Product Monograph
Notice of English-Only Labelling
Extension of Shelf Life to 12 Months
Notice of Lot Number Error on Outer Carton Lot 006H23-2A

Product Concerns

All designated vaccination sites need to maintain security around the storage of SPIKEVAX XBB.1.5 within their facilities.

Make sure that vials of SPIKEVAX XBB.1.5 arrive and are stored in their original packaging. If you suspect that the SPIKEVAX XBB.1.5 you have purchased may be counterfeit, if there are any irregularities with packaging, and/or with the arrival of the shipments, please contact us at 1‑866‑663‑3762 or visit www.modernatx.com, or report a complaint to Health Canada.

Vial Expiration Checker

Find the expiration date here for any vial of Moderna COVID-19 Vaccine through the LOT number of the vial

Reporting Adverse Events

Managing marketed health product-related side effects depends on healthcare professionals and patients reporting them. Any serious or unexpected side effects in patients receiving SPIKEVAX Bivalent should be reported to your local Health Unit.

If a patient experiences a side effect following immunization, please complete the Adverse Events Following Immunization (AEFI) Form appropriate for your province/territory and send it to your local Health Unit.

In addition, you can report side effects to Moderna at Adverse Event Intake Portal or by calling 1-866-MODERNA (1-866-663-3762).